证券代码：688566 证券简称：吉贝尔 公告编号：2025-035 江苏吉贝尔药业股份有限公司 第四届监事会第十六次会议决议公告 本公司监事会及全体监事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 1 表决结果：通过。 一、监事会会议召开情况 江苏吉贝尔药业股份有限公司（以下简称"公司"）第四届监事会第十六次 会议（以下简称"会议"）于 2025 年 8 月 18 日以书面方式发出通知，于 2025 年 8 月 29 日在公司会议室召开。会议应参加表决监事 3 名，实际参加表决监事 3 名。本次会议符合《中华人民共和国公司法》（以下简称"《公司法》"）及《公 司章程》的有关规定，会议合法有效。 （二）审议通过《公司 2025 年半年度利润分配预案》 二、监事会会议审议情况 经与会监事认真审议，以投票表决方式审议通过以下议案： （一）审议通过《公司 2025 年半年度报告及摘要》 根据《公司法》《中华人民共和国证券法》《公开发行证券的公司信息披露内 容与格式准则第 3 号——半年度报告的内容与格式》《上海证券交易所科创板股 票上市规则》等相关法 ...

证券代码：688566 证券简称：吉贝尔 公告编号：2025-036 江苏吉贝尔药业股份有限公司 2025 年半年度利润分配预案公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 每股分配比例：每 10 股派发现金红利人民币 2.60 元（含税），不送 红股，不进行资本公积金转增股本。 如在本公告披露之日起至实施权益分派股权登记日期间公司总股本 发生变动的，公司拟维持分配总额不变，相应调整每股分配比例，并将另行 公告具体调整情况。 一、利润分配预案内容 根据《江苏吉贝尔药业股份有限公司 2025 年半年度报告》，江苏吉贝 尔药业股份有限公司（以下简称"公司"）2025 年半年度实现归属于上市公 司股东的净利润为 149,315,688.00 元（未经审计）；截至 2025 年 6 月 30 日， 公司母公司累计未分配利润为人民币 731,549,978.17 元（未经审计）。公司 拟以实施权益分派股权登记日登记的总股本为基数分配利润。本次利润分配 预案如下： 公司拟以实施权益分派股权登记日登记的总股本为基数 ...

Market Overview - A-share market experienced significant capital divergence on August 28, with the Shanghai Composite Index initially rebounding before dropping over 1% [1] - Afternoon trading saw a rally in technology stocks, leading to a rise in major indices: Shanghai Composite Index up over 1%, Shenzhen Component Index up over 2%, and ChiNext Index up nearly 4% [1] - The trading volume in the ChiNext has significantly increased, driven by the technology stock rally [1] Company Spotlight: Cambricon Technologies - Cambricon's stock price surged by 15.73% on August 28, closing at 1587.91 yuan, surpassing Kweichow Moutai's previous record [3] - The company reported a staggering 4347.82% year-on-year increase in revenue for the first half of 2023, reaching 2.881 billion yuan, with a net profit of 1.038 billion yuan [3] - The revenue growth is attributed to Cambricon's strong product adaptability and collaborative approach, which have facilitated market expansion [3] Industry Insights - Cambricon is a rare domestic cloud AI chip manufacturer, offering a range of AI chip products and platform software for various complex AI applications across multiple sectors [4] - The company’s product lines include cloud products, edge products, IP licensing, and software, catering to industries such as internet, finance, transportation, energy, and manufacturing [4] - East China Securities forecasts significant revenue growth for Cambricon, projecting revenues of 8.443 billion yuan, 16.171 billion yuan, and 25.105 billion yuan for 2025-2027, with corresponding growth rates of 618.91%, 91.52%, and 55.25% [5] AI Industry Trends - The rise of Cambricon has sparked a surge in investor interest in AI-related stocks, with various sectors such as CPO concepts and AI chips experiencing substantial gains [7] - The CPO concept index rose over 6%, with several stocks achieving significant price increases, including Tianfu Communication and Changxin Bochuang, both nearing 20% gains [7] - The AI chip sector, led by Cambricon, saw notable increases, with stocks like Xuanji Information and Fudan Microelectronics rising over 10% [9]

Group 1 - The chemical pharmaceutical sector increased by 2.53% on August 25, with Shutaishen leading the gains [1] - The Shanghai Composite Index closed at 3883.56, up 1.51%, while the Shenzhen Component Index closed at 12441.07, up 2.26% [1] - Notable gainers in the chemical pharmaceutical sector included: - Buzoushen (300204) with a closing price of 61.00, up 16.17% and a trading volume of 445,500 shares [1] - Haichen Pharmaceutical (300584) with a closing price of 58.95, up 13.61% and a trading volume of 217,200 shares [1] - Changshan Pharmaceutical (300255) with a closing price of 53.25, up 12.84% and a trading volume of 683,900 shares [1] Group 2 - The chemical pharmaceutical sector experienced a net outflow of 426 million yuan from institutional investors, while retail investors saw a net inflow of 509 million yuan [2] - The top stocks by net inflow from retail investors included: - Anglikang (002940) with a net inflow of 163 million yuan, representing 22.87% of its trading volume [3] - Haichen Pharmaceutical (300584) with a net inflow of 132 million yuan, representing 10.90% of its trading volume [3] - Lingkang Pharmaceutical (603669) with a net inflow of 64.68 million yuan, representing 37.53% of its trading volume [3]

Core Insights - The company Jibeier (688566.SH) is actively investing in the cell therapy sector, recently participating in a financing round for Shanghai Aisaar Biotechnology Co., Ltd. to capitalize on the upcoming commercialization opportunities in the industry [1] - Aisaar Biotechnology's core product, human umbilical cord mesenchymal stem cell (IxCell hUC-MSC-O) injection, is in Phase III clinical trials for treating knee osteoarthritis, showcasing promising efficacy from previous Phase II trials involving nearly 200 cases [1] - The stem cell therapy market is expected to undergo significant growth, with projections indicating that the global cell therapy market could reach $113.53 billion by 2032, growing at a compound annual growth rate (CAGR) of 23.17% [3] Company Developments - Jibeier has previously invested 81.2 million yuan in Zhejiang Shengchuang Precision Medical Technology Co., Ltd., acquiring a 10.91% stake and actively participating in governance [1] - Shengchuang Technology's self-developed "Menstrual Blood Mesenchymal Stem Cell Injection" (SC01009) has received clinical trial approval for treating decompensated liver cirrhosis post-hepatitis B, marking its fourth new drug registration clinical trial (IND) approval [2] - The unique advantages of the menstrual blood-derived stem cell product include non-invasive collection, rapid proliferation, and low immunogenicity, making it suitable for industrialization and large-scale cultivation [2] Industry Trends - The existing treatments for idiopathic pulmonary fibrosis (IPF) have limited efficacy, with current drugs only able to slow disease progression, while lung transplants face donor shortages [3] - The global IPF drug market is projected to grow at an annual rate exceeding 15%, potentially surpassing $10 billion by 2030, indicating a lucrative opportunity for cell therapies [3] - The domestic stem cell therapy sector is at a critical turning point, with six therapies entering Phase III trials, reflecting a significant increase in clinical advancements after over a decade of technological accumulation [3]

Market Overview - A-shares continue to rise, with the Shanghai Composite Index recording a seven-day winning streak and reaching a new high for the year, closing up 0.5% [2] - A total of 2,084 stocks rose, with 60 hitting the daily limit, while 3,167 stocks declined [3] Stock Performance - The total trading volume reached 19,052.10 billion, with a total of 12,551,627 shares traded [4] - Notable stocks include: - Cambrian (688526) and Xiangyu Medical (688626) both rose by 20% [6] - Innovative Medical (002173) increased by 9.99% [6] - Major gains were also seen in liquid cooling server stocks, with Dayuan Pump Industry (603757) rising by 10% [8] - Semiconductor stocks collectively strengthened, with Cambrian hitting a new high [11] Policy Impact - The Ministry of Industry and Information Technology and six other departments released guidelines to promote the brain-computer interface industry, aiming for breakthroughs in key technologies by 2027 [5] - The U.S. administration's decision to extend the tariff suspension on China for 90 days is seen as a positive factor for the market [13] - The willingness of the U.S. to allow some chip sales to China has alleviated concerns about escalating tech competition and supply chain disruptions [14] Investment Trends - There is a notable increase in institutional and retail investor participation, with significant inflows from insurance, pension funds, and public offerings [14] - The M1-M2 growth rate gap is narrowing, indicating increased liquidity and a recovery in consumer and investment sentiment [14] - The current market trend is expected to continue, with a focus on technology growth as a key policy direction [14] Company News - Fosun International experienced a sharp rise of approximately 20% after reports of its application for a stablecoin license in Hong Kong [16][18]

Core Points - The Shanghai Composite Index closed at 3638.40 points with a change of 0.12% and a total trading volume of 1,206.179 billion yuan [1] - Eight A-shares experienced a crossover where the 5-day moving average fell below the 10-day moving average, indicating potential bearish trends [1] Group 1: Stock Performance - Stock "信立泰" (Code: 002294) decreased by 1.86% with a 5-day moving average of 49.37 yuan and a 10-day moving average of 49.62 yuan, showing a distance of -0.49% [1] - Stock "万邦德" (Code: 002082) decreased by 1.36% with a 5-day moving average of 7.48 yuan and a 10-day moving average of 7.52 yuan, also showing a distance of -0.49% [1] - Stock "毕得医药" (Code: 688073) decreased by 2.96% with a 5-day moving average of 59.09 yuan and a 10-day moving average of 59.27 yuan, indicating a distance of -0.30% [1] Group 2: Additional Stocks with Moving Average Crossovers - Stock "吉贝尔" (Code: 688566) decreased by 3.58% with a 5-day moving average of 33.90 yuan and a 10-day moving average of 33.97 yuan, showing a distance of -0.20% [1] - Stock "诺诚健华" (Code: 688428) decreased by 6.03% with a 5-day moving average of 30.02 yuan and a 10-day moving average of 30.07 yuan, indicating a distance of -0.18% [1] - Stock "丽人丽妆" (Code: 605136) increased by 0.81% with a 5-day moving average of 9.82 yuan and a 10-day moving average of 9.84 yuan, showing a distance of -0.15% [1]

Core Viewpoint - The recent news about Jibeier, a company listed on the Sci-Tech Innovation Board, highlights the upcoming submission of its new antidepressant drug JJH201501 for market approval, alongside the strong performance of its existing products, Likujun tablets and Nigulol tablets, which is generally seen as a positive development [1] Group 1: Company Performance and Market Perception - Despite the positive performance of Jibeier's products, it is emphasized that good current performance does not guarantee future stock price increases, as market perceptions can often overshadow actual performance [3] - The true determinant of stock price movements is not merely the surface performance metrics but rather the real attitudes of institutional investors towards the stock [4] - Historical data shows that during various market phases, a significant number of stocks fail to outperform the market index, indicating that merely holding good companies does not ensure investment success [6] Group 2: Institutional Investment Insights - The performance of stocks like Anglikang, which has seen significant gains, is attributed to the active participation of institutional investors, highlighting the importance of understanding institutional funding dynamics [9] - A stark contrast is drawn between the institutional participation in Anglikang and another vitamin-related company, Huaheng Biological, illustrating how institutional backing can lead to vastly different stock performances [11] - For Jibeier, the critical question remains regarding the behavior of institutional investors: whether they are accumulating shares or quietly withdrawing, as this will significantly impact the stock's future performance [12] Group 3: Investment Strategy Recommendations - Investors are advised to focus on real trading data rather than just news and financial reports, as actions in the market often speak louder than words [12] - Key recommendations include avoiding being misled by superficial news, learning to interpret data effectively, monitoring the real movements of institutional funds, and establishing a personal quantitative analysis system [12]

Core Insights - Zhejiang Shengchuang Precision Medical Technology Co., Ltd. (Shengchuang Technology) has officially launched a Phase II clinical trial for its core product, "Menstrual Blood Mesenchymal Stem Cell Injection," targeting Idiopathic Pulmonary Fibrosis (IPF) [1] - The trial is led by Shanghai Ruijin Hospital and involves 23 top-tier hospitals, indicating a significant advancement in the strategic layout of Shengchuang Technology in the innovative cell therapy field [1] - The global IPF drug market is expected to grow at an annual rate of over 15%, potentially exceeding $10 billion by 2030 [2] Company Overview - Shengchuang Technology focuses on the research and clinical transformation of cell drugs, with its core product being the first domestic menstrual blood stem cell drug to receive clinical trial approval [2] - The company has received early investment from Jibeier, amounting to 81.2 million yuan, and currently holds a 10.91% stake in Shengchuang Technology [1] Clinical Trial Details - The Phase II clinical trial, registered on July 14, 2025, is designed as a multi-center, randomized, double-blind, placebo-controlled study, aiming to evaluate the efficacy, safety, and quality of life impact of SC01009 in IPF patients, with a planned enrollment of 66 participants [1] Market Potential - The treatment of pulmonary fibrosis is in a rapid expansion phase, with existing medications like pirfenidone having limited efficacy and significant side effects, while lung transplants face donor shortages [2] - Cell therapy, which can modulate inflammation, immunity, and fibrosis, is becoming a research hotspot, with promising results in recent studies [2] Unique Advantages - The unique source and multiple biological characteristics of menstrual blood mesenchymal stem cells provide significant advantages, including non-invasive collection, high proliferation capacity, low immunogenicity, and broad differentiation potential [3] - If the Phase II trial of SC01009 is successful, it could not only offer a new treatment for IPF patients but also promote the application of menstrual blood stem cell technology in other disease areas [3]

Core Viewpoint - The company, Jibeier, is demonstrating strong growth momentum driven by both innovative drug development and the upgrade of traditional products, with significant potential in the market for its existing products and upcoming innovations [1][10]. Group 1: Existing Products - The core product, Likujun Tablets, has undergone a five-year redevelopment process, optimizing its production process and increasing its purity from 94% to over 99.6%, securing two national invention patents valid until December 2041 [2][3]. - Likujun Tablets are widely used in the treatment of conditions associated with low white blood cell counts, with a significant market opportunity as it is now recognized as a recommended drug for malignant tumor treatment [2][3]. - In 2024, Likujun Tablets are expected to achieve sales revenue of 652 million yuan, with only about 20,000 patients currently covered in the tumor market, indicating a vast untapped market potential [3][4]. Group 2: Innovative Drug Pipeline - Jibeier has established three major technology platforms for drug development: deuterated drug research, compound formulation research, and liposome drug research, supporting a series of differentiated innovative drugs [5][6]. - The deuterated drug JJH201501, currently in the data summary phase of its Phase III clinical trial, shows promising results with lower doses achieving effects comparable to mainstream antidepressants, indicating a strong market potential in the antidepressant sector [6][7]. - The company is also developing multiple drugs based on its deuterated technology platform, including JJH201701 for acid reduction and JJH202301 for diabetes, creating a tiered research and development structure [7][8]. Group 3: Sales and Market Strategy - In 2024, the company achieved operating revenue of 897 million yuan and a net profit of 215 million yuan, reflecting a balanced focus on both research and sales [9]. - The company plans to enhance its marketing system and promote its existing products, particularly Likujun Tablets and Niqunlor Tablets, to accelerate sales growth [9][10]. - The Chinese innovative drug sector is currently experiencing a golden period of policy benefits, technological breakthroughs, and market demand, positioning Jibeier favorably for long-term growth [10].